Literature DB >> 2106598

Morbidity of patients with analgesic-associated nephropathy on regular dialysis treatment and after renal transplantation.

C Ballé1, P Schollmeyer.   

Abstract

In a retrospective study, patients with end-stage renal failure from analgesic-associated nephropathy - 55 on regular dialysis treatment and 12 after renal transplantation - were under observation for 57 and 33 months, respectively. Of these 34 patients on chronic hemodialysis had suffered from different cardiovascular diseases. Hypertriglyceridemia was diagnosed in 62% of the patients, arterial hypertension requiring antihypertensive therapy in 44%. In three patients (5%) carcinoma of the urinary bladder were diagnosed. The leading causes of death in 21 patients included cardiovascular diseases (29%), hyperkalemia (19%), sepsis, and malignant tumors (14% each). Rejection occurred in 3 out of 12 patients after renal transplantation. Again, cardiovascular morbidity was high (58%) with coronary heart disease being present in 33% of the patients. Hypertriglyceridemia was observed in 5 out of 6 patients, antihypertensive therapy was needed in 50%. One patient died from primary pulmonary hypertension.

Entities:  

Mesh:

Substances:

Year:  1990        PMID: 2106598     DOI: 10.1007/bf01648889

Source DB:  PubMed          Journal:  Klin Wochenschr        ISSN: 0023-2173


  27 in total

1.  Analgesic nephropathy in Wessex: a clinico-pathological survey.

Authors:  H A Lee; A R Davidson; J Burston
Journal:  Clin Nephrol       Date:  1974 Sep-Oct       Impact factor: 0.975

2.  ["Phenacetin kidney" (author's transl)].

Authors:  D Höffler; B Bittner; P Fiegel; H Köhler
Journal:  Dtsch Med Wochenschr       Date:  1973-10       Impact factor: 0.628

3.  [Abuse of analgesics with special reference to analgesic nephropathy].

Authors:  F Scheler; G Schoel
Journal:  Internist (Berl)       Date:  1986-12       Impact factor: 0.743

4.  Increased incidence of cerebral hemorrhage mortality in patients with analgesic nephropathy on hemodialysis.

Authors:  A Chachati; C Dechenne; J P Godon
Journal:  Nephron       Date:  1987       Impact factor: 2.847

5.  Renal cell carcinoma, a new complication of analgesic nephropathy.

Authors:  W Lornoy; S Becaus; M de Vleeschouwer; V Morelle; E Fonteyne; L Thienpoint; J Mestdagh
Journal:  Lancet       Date:  1986-05-31       Impact factor: 79.321

6.  Epidemiologic study of abuse of analgesics containing phenacetin. Renal morbidity and mortality (1968-1979).

Authors:  U C Dubach; B Rosner; E Pfister
Journal:  N Engl J Med       Date:  1983-02-17       Impact factor: 91.245

7.  Analgesic-associated nephropathy and transitional cell carcinoma of the urinary tract.

Authors:  T A Gonwa; W T Corbett; H M Schey; V M Buckalew
Journal:  Ann Intern Med       Date:  1980-08       Impact factor: 25.391

8.  Phenacetin abuse and malignant tumors. An autopsy study covering 25 years (1953-1977).

Authors:  M J Mihatsch; C Knüsli
Journal:  Klin Wochenschr       Date:  1982-11-02

9.  [Increased cardiovascular arteriosclerosis risk in patients with analgesic nephropathy (author's transl)].

Authors:  A Helber; G Wambach; W Böttcher; K Finke; R Hahn
Journal:  Dtsch Med Wochenschr       Date:  1981-10-16       Impact factor: 0.628

Review 10.  Renal effects of antipyretic analgesics.

Authors:  R S Nanra
Journal:  Am J Med       Date:  1983-11-14       Impact factor: 4.965

View more
  1 in total

1.  The effect of hyperkalemia and long inter-dialytic interval on morbidity and mortality in patients receiving hemodialysis: a systematic review.

Authors:  Danai Bem; Daniel Sugrue; Ben Wilding; Ina Zile; Karin Butler; David Booth; Eskinder Tafesse; Phil McEwan
Journal:  Ren Fail       Date:  2021-12       Impact factor: 2.606

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.